AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35804457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride (NSF)
Number of subjects: 50
Study 35804457 — intervention group
Group type: COMPARATOR
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 50
Study 35805716 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute triiodothyronine (T3) treatment
Number of subjects: 0
Study 35805716 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 administration
Number of subjects: 0
Study 35806269 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole)
Number of subjects: 209
Study 35808889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 98
Study 35808998 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) combined with prolonged exposure (PE) therapy
Number of subjects: 16
Study 35808998 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study 35809096 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP patients
Number of subjects: 40
Study 35809937 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Oral Corticosteroids
Number of subjects: 0
Study 35809937 — intervention group
Group type: COMPARATOR
Intervention: Biologics
Number of subjects: 0
Study 35810079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue subcutaneous (s.c.) progesterone therapy (25 mg)
Number of subjects: 238
Study 35810079 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone tablet plus i.m. progesterone (control group)
Number of subjects: 238
Study 35810243 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK (Descemet membrane endothelial keratoplasty)
Number of subjects: 43
Study 35810296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SO) titrated to a goal serum phosphate of <5.5 mg/dL
Number of subjects: 17
Study 35810311 — intervention group
Group type: EXPERIMENTAL
Intervention: Miridesap/dezamizumab
Number of subjects: 23
Study 35810553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nazartinib 150 mg once daily
Number of subjects: 45
Study 35810555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic fasting-mimicking diet (FMD) combined with standard anticancer therapies
Number of subjects: 101
Study 35810555 — intervention group
Group type: COMPARATOR
Intervention: Standard anticancer therapies
Number of subjects: 101
Study 35810953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-profile (LP) devices
Number of subjects: 466
Study 35810953 — intervention group
Group type: COMPARATOR
Intervention: Standard-profile (SP) devices
Number of subjects: 466
Study 35811565 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0
Study 35811565 — intervention group
Group type: COMPARATOR
Intervention: Culprit-vessel-only revascularization
Number of subjects: 0
Study 35812102 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 516
Study 35812102 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID controls
Number of subjects: 516
Study 35812443 — intervention group
Group type: EXPERIMENTAL
Intervention: TILTregSig (prognostic signature of Tregs consisting of five mRNAs)
Number of subjects: 0
Study 35812817 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat (EXB) 10 mg/day for 4 weeks
Number of subjects: 40
Study 35812823 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous in-vehicle technologies (Level 1) activated
Number of subjects: 105
Study 35812823 — intervention group
Group type: COMPARATOR
Intervention: No autonomous in-vehicle technologies activated (control condition)
Number of subjects: 105
Study 35813254 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal Robotic-assisted Laparoscopic Pyeloplasty (T-RALP)
Number of subjects: 106
Study 35813254 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal Robotic-assisted Laparoscopic Pyeloplasty (R-RALP)
Number of subjects: 106
Study 35813373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 1 week
Number of subjects: 300
Study 35813373 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus gentamicin (standard-of-care)
Number of subjects: 300
Study 35813634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (weight loss associated with lifestyle changes)
Number of subjects: 12
Study 35814366 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC 3-g supplementation by mouth once daily on empty stomach for 6 months
Number of subjects: 50
Study 35814366 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 months
Number of subjects: 50
Study 35814366 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC supplementation (unblinded) for 6 months after placebo
Number of subjects: 50
Study 35814366 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC supplementation overall (blinded and unblinded)
Number of subjects: 50
Study 35814366 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of IFN-β to less than 20 pg/ml
Number of subjects: 50
Study 35814730 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 2479
Study 35814730 — intervention group
Group type: COMPARATOR
Intervention: Control for housing, relationship status, age, childhood abuse, and potential effect of IPV on later food insecurity
Number of subjects: 2479
Study 35814763 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging using infrared scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT) over a mean period of 32.8 months (range, 18-72 months) with a mean interval between imaging sessions of 2.4 months (range, 1.4-3.8 months).
Number of subjects: 6
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-related psychosocial care (COVID-psyCare) provided in hospitals
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cooperation structures for COVID-psyCare
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-psyCare for patients
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-psyCare for relatives
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-psyCare for staff
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: Time resources invested for patients, relatives, and staff
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging needs for mutual exchange and support regarding COVID-psyCare
Number of subjects: 98
Study 35815043 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for future changes or improvements in COVID-psyCare
Number of subjects: 98
Study 35815359 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pharmacological treatments for COPD
Number of subjects: 20054
Study 35815359 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 20054
Study 35815359 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model
Number of subjects: 20054
Study 35815359 — intervention group
Group type: COMPARATOR
Intervention: Simplified model
Number of subjects: 20054
Study 35815403 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium Trial participants
Number of subjects: 1215
Study 35815403 — intervention group
Group type: COMPARATOR
Intervention: Independent case-control study population from CORSA
Number of subjects: 1215
Study 35815408 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-ING-41, a selective GSK-3β inhibitor
Number of subjects: 1
Study 35815468 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (F, FTC)-tenofovir disoproxil fumarate (TDF)
Number of subjects: 0
Study 35815468 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 35815644 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 764532 (DLL3/CD3 bispecific T-cell engager)
Number of subjects: 0
Study 35815666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized feminizing hormone therapy (sFHT; oestradiol valerate 2-6 mg plus spironolactone 100-300 mg) plus PrEP for 12 weeks
Number of subjects: 43
Study 35815666 — intervention group
Group type: EXPERIMENTAL
Intervention: Any feminizing hormone therapy (aFHT) plus PrEP (long-term PK)
Number of subjects: 43
Study 35815666 — intervention group
Group type: COMPARATOR
Intervention: PrEP only (noFHT)
Number of subjects: 43
Study 35815954 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge-eating symptoms (BE)
Number of subjects: 482
Study 35815954 — intervention group
Group type: COMPARATOR
Intervention: No binge-eating symptoms (Control group)
Number of subjects: 482
Study 35816217 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (specific dosage and duration not mentioned)
Number of subjects: 0
Study 35816241 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) with immune-enhancing feed plus maltodextrin load on the day of surgery (Group A)
Number of subjects: 2
Study 35816241 — intervention group
Group type: COMPARATOR
Intervention: No immunonutrition nor fast track management (Group B)
Number of subjects: 2
Study 35816241 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) with ERAS protocol (Group A)
Number of subjects: 2
Study 35816269 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging (NIRF-LI) surveillance
Number of subjects: 42
Study 35816269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal backflow detected by NIRF-LI
Number of subjects: 42
Study 35816378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovation Alto stent graft
Number of subjects: 300
Study 35816381 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity program including 3 types of exercises: staying out of bed for at least 3 hours, performing balance exercises while standing for 2 minutes, and the Five Times Sit to Stand transfer exercise.
Number of subjects: 266
Study 35816381 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity program
Number of subjects: 266
Study 35816381 — intervention group
Group type: EXPERIMENTAL
Intervention: Five Times Sit to Stand test
Number of subjects: 266
Study 35816397 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nutritional intervention based on Mediterranean diet (MD) enriched with extra virgin olive oil (EVOO)
Number of subjects: 0
Study 35816397 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35816411 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCoV vaccine
Number of subjects: 0
Study 35816490 — intervention group
Group type: EXPERIMENTAL
Intervention: APN01 (soluble human recombinant ACE2) administered via nebulizer, twice daily for two weeks at maximum feasible concentration
Number of subjects: 0
Study 35816490 — intervention group
Group type: EXPERIMENTAL
Intervention: APN01 (soluble human recombinant ACE2)
Number of subjects: 0
Study 35816664 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprenetapopt plus azacitidine
Number of subjects: 33
Study 35816681 — intervention group
Group type: EXPERIMENTAL
Intervention: You + ME Registry
Number of subjects: 4339
Study 35816737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overeating for one week in exercise trained adults (EX)
Number of subjects: 0
Study 35816737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overeating for one week in untrained adults (UT)
Number of subjects: 0
Study 35816744 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent exercise training (MCT)
Number of subjects: 93
Study 35816744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 35816831 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco®)
Number of subjects: 72
Study 35816941 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 27
Study 35816941 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched, no ADHD)
Number of subjects: 27
Study 35816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberknife System treatment plans based on unrotated volume
Number of subjects: 0
Study 35816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberknife System treatment plans based on envelope of unrotated and rotated volumes
Number of subjects: 0
Study 35816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma analysis of treatment plans
Number of subjects: 0
Study 35816951 — intervention group
Group type: EXPERIMENTAL
Intervention: Retifanlimab 500 mg administered intravenously every 4 weeks
Number of subjects: 94
Study 35817031 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and osteoprotegerin
Number of subjects: 4957
Study 35817031 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefoil factor 3
Number of subjects: 4957
Study 35817031 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 4957
Study 35817031 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP plus clinical risk factors
Number of subjects: 4957
Study 35817031 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biomarkers
Number of subjects: 4957
Study 35817091 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood or kerosene cooking fuel
Number of subjects: 798
Study 35817091 — intervention group
Group type: COMPARATOR
Intervention: Age (per year increase)
Number of subjects: 798
Study 35817091 — intervention group
Group type: COMPARATOR
Intervention: Baseline myopia
Number of subjects: 798
Study 35817091 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 798
Study 35817480 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Number of subjects: 2
Study 35817563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic total gastrectomy (PTG)
Number of subjects: 120
Study 35818046 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience assessment using the 25-item Connor-Davidson resilience scale (CD-RISC)
Number of subjects: 143
Study 35818046 — intervention group
Group type: COMPARATOR
Intervention: Frail patients
Number of subjects: 143
Study 35818046 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 143
Study 35818348 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care nerve conduction study device (Mediracer® NCS)
Number of subjects: 12
Study 35818348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OX) treatment
Number of subjects: 12
Study 35818348 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-CIPN20 questionnaire
Number of subjects: 12
Study 35818348 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSI questionnaire
Number of subjects: 12
Study 35818509 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin
Number of subjects: 0
Study 35818548 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated peak oxygen consumption (Vo2) using HF-FRIEND or oncology-specific equations
Number of subjects: 0
Study 35818548 — intervention group
Group type: COMPARATOR
Intervention: Measured peak oxygen consumption (Vo2)
Number of subjects: 0
Study 35818888 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based stigma and disclosure strategies
Number of subjects: 83
Study 35818888 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive relationships
Number of subjects: 83
Study 35818888 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV care engagement strategies
Number of subjects: 83
Study 35818888 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for school-going adolescents
Number of subjects: 83
Study 35818888 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management strategies
Number of subjects: 83
Study 35819130 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly digital follow-up of lung cancer patients
Number of subjects: 201
Study 35819130 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly digital follow-up of lung cancer patients (pilot study)
Number of subjects: 201
Study 35819199 — intervention group
Group type: EXPERIMENTAL
Intervention: PROACTIA score
Number of subjects: 236
Study 35819199 — intervention group
Group type: EXPERIMENTAL
Intervention: P-wave duration, PAC/24h, NT-proBNP, LAVI
Number of subjects: 236
Study 35819199 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc, P-wave duration, P-wave morphology, PAC/24h, supraventricular tachycardia/24h, left atrial end-systolic volume index (LAVI), Troponin-T, NT-proBNP, D-dimer
Number of subjects: 236
Study 35819199 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 236
Study 35819312 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation pathology (NGP) detection of immune synapses (ai-iSYN)
Number of subjects: 53
Study 35819312 — intervention group
Group type: EXPERIMENTAL
Intervention: NGP-detected immune synapses
Number of subjects: 53
Study 35819312 — intervention group
Group type: COMPARATOR
Intervention: iPAIRs
Number of subjects: 53
Study 35819312 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAC formation in iPAIR-engaged lymphocytes
Number of subjects: 53
Study 35819325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (PAH) and PH secondary to lung disease
Number of subjects: 1823
Study 35819325 — intervention group
Group type: COMPARATOR
Intervention: Control group (230 patients)
Number of subjects: 1823
Study 35819446 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-146b-5p mimic administration to NSG mice engrafted with CLL cells
Number of subjects: 224
Study 35819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulation of miR-146b-5p with specific miRNA inhibitors in vitro
Number of subjects: 224
Study 35819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of miR-146b-5p with miRNA mimics in vitro
Number of subjects: 224
Study 35819446 — intervention group
Group type: COMPARATOR
Intervention: Observation of miR-146b-5p concentrations in untreated patients
Number of subjects: 224
Study 35819490 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laparoscopy (PERC)
Number of subjects: 59
Study 35819490 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (LAP)
Number of subjects: 59
Study 35819829 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-ECO intervention (n=4 ECECs)
Number of subjects: 130
Study 35819829 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=4 ECECs)
Number of subjects: 130
Study 35819829 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-ECO intervention
Number of subjects: 130
Study 35820054 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal patient portal intervention for distance monitoring of self-isolating patients with COVID-19, involving daily self-assessment of symptoms, vital signs, and mental health monitored by a nurse, with teleconsultations as needed.
Number of subjects: 50
Study 35820054 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted with stakeholders (patient participants, health care professionals, technology developers, study administrators).
Number of subjects: 50
Study 35820082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Number of subjects: 0
Study 35820227 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent productive cough (defined as cough and sputum production most or several days/week for the past 3 months)
Number of subjects: 7125
Study 35820227 — intervention group
Group type: COMPARATOR
Intervention: Patients without frequent productive cough
Number of subjects: 7125
Study 35820397 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib
Number of subjects: 50
Study 35820397 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib (near-loop insertions)
Number of subjects: 50
Study 35820397 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib (far-loop insertions)
Number of subjects: 50
Study 35820684 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochures and short educational sessions for medical staff on safe gabapentinoid prescribing practices.
Number of subjects: 160
Study 35820684 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 160
Study 35820718 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion (1×10^6 cells)
Number of subjects: 6
Study 35820718 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion
Number of subjects: 6
Study 35820756 — intervention group
Group type: EXPERIMENTAL
Intervention: Operationalise a functional malaria molecular surveillance system in Mozambique
Number of subjects: 0
Study 35820771 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35820779 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for NASH using PLIN2 mean fluorescence intensity (MFI) combined with waist circumference, triglyceride, alanine aminotransferase (ALT), and presence/absence of diabetes as covariates
Number of subjects: 250
Study 35820779 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm including RAB14 MFI, age, waist circumference, high-density lipoprotein cholesterol, plasma glucose, and ALT levels as covariates to predict liver fibrosis
Number of subjects: 250
Study 35820779 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed novel liquid biopsy
Number of subjects: 250
Study 35820867 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT score
Number of subjects: 5250
Study 35820867 — intervention group
Group type: COMPARATOR
Intervention: CAN score
Number of subjects: 5250
Study 35820889 — intervention group
Group type: EXPERIMENTAL
Intervention: APG-2449
Number of subjects: 0
Study 35820889 — intervention group
Group type: EXPERIMENTAL
Intervention: APG-2449 in combination with paclitaxel
Number of subjects: 0
Study 35820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health training integration in TB services
Number of subjects: 162
Study 35820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for mental health conditions in TB patients
Number of subjects: 162
Study 35820917 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through focus groups and interviews
Number of subjects: 162
Study 35821349 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH-ant) protocol
Number of subjects: 0